These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28105226)

  • 1. Expression of epidermal growth factor-like domain 7 may be a predictive marker of the effect of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.
    Yamauchi M; Fukuda T; Wada T; Kawanishi M; Imai K; Tasaka R; Yasui T; Sumi T
    Oncol Lett; 2016 Dec; 12(6):5183-5189. PubMed ID: 28105226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of mitotic-arrest deficiency 2 predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.
    Morishita M; Sumi T; Nakano Y; Teramae M; Fukuda T; Nobeyama H; Yoshida H; Matsumoto Y; Yasui T; Ishiko O
    Exp Ther Med; 2012 Feb; 3(2):341-346. PubMed ID: 22969893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UCP2 expression may represent a predictive marker of neoadjuvant chemotherapy effectiveness for locally advanced uterine cervical cancer.
    Imai K; Fukuda T; Wada T; Kawanishi M; Tasaka R; Yasui T; Sumi T
    Oncol Lett; 2017 Jul; 14(1):951-957. PubMed ID: 28693257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirtuin1 expression predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.
    Teramae M; Fukuda T; Wada T; Kawanishi M; Imai K; Yamauchi M; Yasui T; Sumi T
    Mol Clin Oncol; 2015 Jan; 3(1):73-78. PubMed ID: 25469273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XPA expression is a predictive marker of the effectiveness of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.
    Wada T; Fukuda T; Shimomura M; Inoue Y; Kawanishi M; Tasaka R; Yasui T; Ikeda K; Sumi T
    Oncol Lett; 2018 Mar; 15(3):3766-3771. PubMed ID: 29556276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HIF-1α is a predictive marker of the efficacy of neoadjuvant chemotherapy for locally advanced cervical cancer.
    Yan B; Ma QF; Tan WF; Cai HN; Li YL; Zhou ZG; Dai X; Zhu FX; Xiong YJ; Xu M; Guo YL; Gao H; Hu JB; Wu XF
    Oncol Lett; 2020 Jul; 20(1):841-849. PubMed ID: 32566011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRMT1 expression predicts response to neoadjuvant chemotherapy for locally advanced uterine cervical cancer.
    Shimomura M; Fukuda T; Awazu Y; Nanno S; Inoue Y; Matsubara H; Yamauchi M; Yasui T; Sumi T
    Oncol Lett; 2021 Feb; 21(2):150. PubMed ID: 33552268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-box 2 expression is a useful indicator of the response to neoadjuvant chemotherapy for patients with locally advanced uterine cervical squamous cell carcinoma.
    Inoue Y; Fukuda T; Nanno S; Awazu Y; Shimomura M; Matsubara H; Yamauchi M; Yasui T; Sumi T
    Oncol Lett; 2021 Nov; 22(5):755. PubMed ID: 34539859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer.
    Sugiyama T; Nishida T; Hasuo Y; Fujiyoshi K; Yakushiji M
    Gynecol Oncol; 1998 May; 69(2):130-6. PubMed ID: 9600820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fyn expression is associated with the response of patients with locally advanced uterine cervical squamous cell carcinoma to neoadjuvant chemotherapy.
    Nanno S; Fukuda T; Noda T; Uchikura E; Awazu Y; Imai K; Yamauchi M; Yasui T; Sumi T
    Mol Clin Oncol; 2022 Oct; 17(4):147. PubMed ID: 36157319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
    Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
    Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of the Epidermal Growth Factor-like Domain 7 and Inhibition of Migration and Epithelial-Mesenchymal Transition in Human Pancreatic Cancer PANC-1 Cells.
    Wang YL; Dong FL; Yang J; Li Z; Zhi QM; Zhao X; Yang Y; Li DC; Shen XC; Zhou J
    Asian Pac J Cancer Prev; 2015; 16(9):4065-9. PubMed ID: 25987088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer.
    Abou-Taleb HA; Koshiyama M; Matsumura N; Baba T; Yamaguchi K; Hamanishi J; Abiko K; Yamanoi K; Murakami R; Horikawa N; Taha AA; Kitamura S; Konishi I
    J Int Med Res; 2016 Apr; 44(2):346-56. PubMed ID: 26831404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Contribution of sentinel lymph-node biopsy to treatment of locally advanced stages of cervical cancers].
    Sláma J; Zikán M; Fischerová D; Kocián R; Germanová A; Frühauf F; Cibula D
    Ceska Gynekol; 2016; 81(3):165-170. PubMed ID: 27882757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy.
    Hansen TF; Carlsen AL; Tanassi JT; Larsen O; Sørensen FB; Jensen LH; Jakobsen A
    Cancer Drug Resist; 2019; 2(3):885-896. PubMed ID: 35582589
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidermal growth factor-like domain 7 regulates breast cancer cell proliferation and vascular endothelial growth factor expression via the p38MAPK signaling pathway.
    Zhou B; Wang J
    Am J Transl Res; 2021; 13(4):2608-2616. PubMed ID: 34017420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
    Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-institutional phase II study of neoadjuvant irinotecan and nedaplatin followed by radical hysterectomy and the adjuvant chemotherapy for locally advanced, bulky uterine cervical cancer: A Kansai Clinical Oncology Group study (KCOG-G1201).
    Mori T; Makino H; Okubo T; Fujiwara Y; Sawada M; Kuroboshi H; Tsubamoto H; Murakoshi H; Motohashi T; Kitawaki J; Ito K
    J Obstet Gynaecol Res; 2019 Mar; 45(3):671-678. PubMed ID: 30575239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.
    Chen H; Liang C; Zhang L; Huang S; Wu X
    Gynecol Oncol; 2008 Sep; 110(3):308-15. PubMed ID: 18606439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFL7 regulates sprouting angiogenesis and endothelial integrity in a human blood vessel model.
    Usuba R; Pauty J; Soncin F; Matsunaga YT
    Biomaterials; 2019 Mar; 197():305-316. PubMed ID: 30684886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.